论文部分内容阅读
新近研究认为,炎症参与了糖尿病患者并发动脉粥样硬化的病理过程,CD40配体作为一种新的炎症标志,广泛存在于T、B淋巴细胞、内皮细胞、平滑肌细胞、单核/巨噬细胞、血小板及上皮细胞表面,它与其受体相互作用可诱导上述细胞产生许多致炎因子,参与动脉粥样硬化的发展变化。最新临床研究提示CD40配体可能参与糖尿病炎性血管并发症的发生。阻断CD40-CD40配体的相互作用可能为抑制糖尿病并发动脉粥样硬化的发生与发展提供新的治疗手段。
Recent studies suggest that inflammation is involved in the pathogenesis of atherosclerosis in diabetic patients. As a new inflammatory marker, CD40 ligand is widely found in T, B lymphocytes, endothelial cells, smooth muscle cells, monocytes / macrophages , Platelets and the surface of epithelial cells, which interacts with their receptors to induce the above-mentioned cells to produce many proinflammatory cytokines involved in the development of atherosclerosis. Recent clinical studies suggest that CD40 ligand may be involved in the occurrence of diabetic vascular complications. Blocking the interaction of CD40-CD40 ligands may provide new therapeutic tools for inhibiting the occurrence and development of diabetes and atherosclerosis.